Identify and treat patients with confidence
KISQALI is proven to help the broadest range of patients with stage II/III HR+/HER2- eBC
Identify eligible patients like Jasmine, Erin, and Katrice today
Stage II (T2N1)
Find out why KISQALI is right for Jasmine
She was recently diagnosed with stage II (T2N1) HR+/HER2- eBC.
Stage II (T2N0)
Find out why KISQALI is right for Erin
She was recently diagnosed with stage II (T2N0) HR+/HER2- eBC.
Stage III (T2N2)
Find out why KISQALI is right for Katrice
She was recently diagnosed with stage III (T2N2) HR+/HER2- eBC.
NATALEE was a randomized, multicenter, open-label, phase III study of KISQALI + letrozole or anastrozole (n=2549) vs letrozole or anastrozole (n=2552) for the adjuvant treatment of men and women with stage II/III HR+/HER2- eBC. At a median follow-up of 33.3 months, with 509 iDFS (primary end point) events in the study (226 [8.9%] in the KISQALI arm and 283 [11.1%] in the NSAI-alone arm), iDFS at the 3-year landmark was 90.7% for KISQALI + NSAI vs 87.6% for NSAI alone (absolute difference 3.1%); there was a 25.1% relative reduction in the risk of an iDFS event; HR=0.749 (95% CI: 0.628-0.892).1-3